AstraZeneca Pharma India Limited has inaugurated a new corporate office in Mumbai.
Thus, marking a fresh phase in its India growth strategy as the global biopharmaceutical company looks to accelerate healthcare innovation, expand access to life-saving treatments and deepen partnerships across the healthcare ecosystem.
The 25,600 sq ft office was inaugurated by Maharashtra Chief Minister Devendra Fadnavis, alongside senior government officials, diplomatic dignitaries and AstraZeneca representatives.
The move comes as AstraZeneca expands its research and commercial presence in India. The company has introduced more than 25 new medicines and indications in the country over the past three years and is currently running around 80 global clinical trials in India, strengthening the country’s role in global drug development.
The new Mumbai base is expected to bring AstraZeneca closer to healthcare stakeholders, support talent development and strengthen collaboration across its key therapy areas: oncology, biopharmaceuticals and rare diseases.
Devendra Fadnavis, Chief Minister of Maharashtra, said “Maharashtra has a strong and growing pharmaceutical and life sciences ecosystem, supported by skilled talent, leading institutions and robust healthcare infrastructure. AstraZeneca’s decision to establish its India commercial office in Mumbai reflects confidence in the state’s capabilities and its potential as an innovation hub.
"We welcome AstraZeneca’s continued commitment to Maharashtra and look forward to the opportunities this will create for collaboration, capability building and skilled employment.”
AstraZeneca said its stronger presence in Mumbai would help it respond to India’s evolving healthcare needs, particularly the demand for earlier diagnosis, innovative treatments and more equitable access to medicines.
“India is at an important inflection point in healthcare, with a growing need for earlier diagnosis, innovative treatments and more equitable access,” said Praveen Rao Akkinepally, Country President and Managing Director, AstraZeneca Pharma India Limited.
"Our stronger presence in Mumbai strengthens our ability to work with partners across the healthcare ecosystem and advance solutions that address the needs of patients in India. Our strong workforce of nearly 5,000 colleagues across the country are united by a common ambition to follow the science, advance access to life saving therapies and help more people live better, healthier lives.”
The company is also looking to leverage artificial intelligence and develop solutions spanning prevention, awareness, diagnosis and treatment. Working with governments and industry partners, it aims to create new pathways to bring life-saving therapies to more patients.
The Mumbai office is expected to strengthen engagement with India’s fast-evolving healthcare ecosystem as AstraZeneca builds on its presence across its three core therapy areas.
Arun Krishna, Non-Executive Director on the Board of AstraZeneca Pharma India Limited and Area Vice President, Asia, AstraZeneca, said “India is an increasingly important contributor to AstraZeneca’s growth across Asia. The momentum of our business, the evolution of our portfolio, and the depth of talent and capabilities in the country provides a strong foundation for the opportunity ahead.
"Our new commercial office in Mumbai will support closer engagement with stakeholders and the continued development of our people, strengthening India’s contribution to our regional and global ambition.”
Beyond commercial expansion, AstraZeneca said the new office would support its continued investment in talent and capability building in India, opening opportunities for professionals working at the intersection of science, technology and healthcare.
The company plans to attract and develop diverse talent across its operations as it expands its footprint in the country.
